Somewhat Positive News Coverage Somewhat Unlikely to Impact Alere (ALR) Share Price
Media stories about Alere (NYSE:ALR) have trended somewhat positive this week, Accern reports. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alere earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 46.7829425453731 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- The Technical Condition Changes For Gardner Denver Holdings … – AllStockNews (allstocknews.com)
- Alere Inc. (ALR) has a value of $49.49 per share While Corbus Pharmaceuticals Holdings, Inc. (CRBP) is stand at $5.97 – Stocks Gallery (stocksgallery.com)
- Alere Inc. (NYSE:ALR) Experiences Heavy Trading Volume – Modern Readers (modernreaders.com)
- Zacks Investment Research Lowers Alere Inc. (ALR) to Sell (americanbankingnews.com)
- Alere Inc Has Returned 27.3% Since SmarTrend Recommendation (ALR) (mysmartrend.com)
Shares of Alere (NYSE:ALR) traded down 0.58% on Thursday, reaching $49.33. 1,229,463 shares of the company were exchanged. The company’s 50-day moving average price is $50.10 and its 200 day moving average price is $45.67. The company’s market cap is $4.32 billion. Alere has a 12 month low of $34.41 and a 12 month high of $50.63.
ALR has been the subject of several analyst reports. BidaskClub cut shares of Alere from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. Canaccord Genuity reiterated a “buy” rating and set a $51.00 price target on shares of Alere in a research report on Monday, May 22nd. Zacks Investment Research cut shares of Alere from a “hold” rating to a “strong sell” rating in a research report on Wednesday, April 19th. BTIG Research reiterated a “neutral” rating on shares of Alere in a research report on Monday, May 15th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $51.00 price target on shares of Alere in a research report on Thursday, June 1st. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $48.00.
Alere Inc is a provider of health information through diagnostic tests. The Company’s segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus.
Receive News & Ratings for Alere Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alere Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.